CURE’s myeloproliferative neoplasms (MPN) page is an extensive resource of cancer information featuring the latest MPN news, expert oncologist insights on the latest cancer treatments, oncology research, advocacy efforts, and medical data on myeloproliferative neoplasms.
February 23rd 2024
Treatment with rusfertide led to a decrease in the need for blood draws and decreased levels of red blood cells in patients with polycythemia vera.
December 23rd 2023
Elderly Patients Significantly Underrepresented in Hematology Clinical Trials
December 12th 2017Patients aged 75 years or older diagnosed with hematologic malignancies appear significantly underrepresented in clinical trials submitted to the U.S. Food and Drug Administration (FDA), according to a retrospective analysis.
Prevymis Approved to Prevent Virus in Patients Receiving Stem Cell Transplants
November 9th 2017Prevyis (letermovir) was granted approval by the Food and Drug Administration (FDA) to prevent cytomegalovirus (CMV) infection in adult CMV-seropositive patients treated with an allogeneic hematopoietic stem cell transplant (HSCT). The result is based on a significant reduction in CMV infection rates in a phase 3 study.
Older Adults with AML Don't Understand the Risks and Likely Outcomes of Treatment
October 24th 2017Older patients with acute myeloid leukemia (AML) often face a difficult choice: risky, intensive chemotherapy that offers a small chance of a cure versus non-intensive chemotherapy meant to improve physical comfort and quality of life.
Expert Gives an Overview of New Drugs to Treat AML
October 9th 2017For the past four decades, there have been few advances in the treatment field of acute myeloid leukemia (AML). However, in the year 2017, there have been four new drugs approved by the FDA to treat the disease, with even more promising agents in the pipeline.
Drug Provides High Response Rate in CLL
September 25th 2017Venclexta (venetoclax), a BCL-2 inhibitor, had promising results in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). According to an updated analysis of a clinical trial, the agent led to negative minimal residual disease (MRD) in 40 percent of patients involved.
Bosulif Granted Priority Review in CML
August 30th 2017Bosulif (bosutinib) was granted a priority review to a supplemental new drug application (sNDA) by the Food and Drug Administration (FDA) for use in the first-line treatment of patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML).
End-of-Life Care Is Suboptimal in Elderly Patients With AML
August 25th 2017End-of-life care is of particular concern for elderly patients with AML because prognosis is poor and has not changed in several decades. Median survival for patients 65 or older is roughly two months and drops to as low as one month for patients over 85 years.
Exciting Advances Are Coming for First-line CML Treatment
August 10th 2017Kendra Sweet, M.D., discussed the various factors that must be taken into account when prescribing first-line therapies to patients with CML, the novel studies that are paving the way for improved outcomes in patients, and the increasing likelihood for TKI discontinuation on the horizon.